The DOI matches its Crossref record; 156 of the 160 references it cites were found in a registry or an index.
Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices.
Open accessAbstract
HEPATITIS B VIRUS (HBV) IS TRANSMITTED VIA BLOOD OR SEXUAL CONTACT. PERSONS WITH CHRONIC HBV INFECTION ARE AT INCREASED RISK FOR CIRRHOSIS AND LIVER CANCER AND REQUIRE MEDICAL CARE. THIS REPORT UPDATES AND SUMMARIZES PREVIOUSLY PUBLISHED RECOMMENDATIONS FROM THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) AND CDC REGARDING THE PREVENTION OF HBV INFECTION IN THE UNITED STATES. ACIP RECOMMENDS TESTING ALL PREGNANT WOMEN FOR HEPATITIS B SURFACE ANTIGEN (HBSAG), AND TESTING HBSAG-POSITIVE PREGNANT WOMEN FOR HEPATITIS B VIRUS DEOXYRIBONUCLEIC ACID (HBV DNA); ADMINISTRATION OF HEPB VACCINE AND HEPATITIS B IMMUNE GLOBULIN (HBIG) FOR INFANTS BORN TO HBV-INFECTED WOMEN WITHIN 12 HOURS OF BIRTH, FOLLOWED BY COMPLETION OF THE VACCINE SERIES AND POSTVACCINATION SEROLOGIC TESTING; UNIVERSAL HEPATITIS B VACCINATION WITHIN 24 HOURS OF BIRTH, FOLLOWED BY COMPLETION OF THE VACCINE SERIES; AND VACCINATION OF CHILDREN AND ADOLESCENTS AGED <19 YEARS WHO HAVE NOT BEEN VACCINATED PREVIOUSLY. ACIP RECOMMENDS VACCINATION OF ADULTS AT RISK FOR HBV INFECTION, INCLUDING UNIVERSAL VACCINATION OF ADULTS IN SETTINGS IN WHICH A HIGH PROPORTION HAVE RISK FACTORS FOR HBV INFECTION AND VACCINATION OF ADULTS REQUESTING PROTECTION FROM HBV WITHOUT ACKNOWLEDGMENT OF A SPECIFIC RISK FACTOR. THESE RECOMMENDATIONS ALSO PROVIDE CDC GUIDANCE FOR POSTEXPOSURE PROPHYLAXIS FOLLOWING OCCUPATIONAL AND OTHER EXPOSURES. THIS REPORT ALSO BRIEFLY SUMMARIZES PREVIOUSLY PUBLISHED AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASEST GUIDELINES FOR MATERNAL ANTIVIRAL THERAPY TO REDUCE PERINATAL HBV TRANSMISSION.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![FIGURE 3 Pre-exposure evaluation for health care personnel previously vaccinated with complete, ≥3-dose HepB vaccine series who have not had postvaccination serologic testing* * Should be performed 1–2 months after the last dose of vaccine using a quantitative method that allows detection of the protective concentration of anti-HBs (≥10 mIU/mL) (e.g., enzyme-linked immunosorbent assay [ELISA]).](https://figures.cochat.ai/paper-figures/33a10c0a9fbd4aaeaee38fc22efcfceb/prevention-of-hepatitis-b-virus-infection-in-the-united-states-recommendations-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, vaccination coverage among the majority of adult populations at high risk aged ≥30 years (e.g., persons with multiple sex partners, MSM, and injecting drug users) has remained low (1320,1321); these groups account for the highest rates of preventable acute infections (12,1319,1322).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both passive and active PEP (simultaneous administration of HBIG [i.e., 0.06 mL/kg body weight] and hepatitis B vaccine at separate anatomic sites) and active PEP (administration of hepatitis B vaccination alone) have been demonstrated to be highly effective in preventing transmission after exposure to HBV (12).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent clinical trials reported a protective antibody response achieved among approximately 90% of participants receiving Heplisav-B, compared with 70.5%–90.2% of participants receiving Engerix-B (12).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
(1994) · PsycEXTRA Dataset · doi:10.1037/e546992006-001 · Cited by 1,714
Trépo, C., Chan, H. L. Y., & Lok, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60220-8 · Cited by 1,623
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
Rubin, L. G., Levin, M. J., Ljungman, P., Davies, E. G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit684 · Cited by 1,613
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267 · cited 2×
“8%) of persons who inject drugs (PWID) in a variety of settings (75) and 22.”
BackgroundMast, E. E., Weinbaum, C. M., Fiore, A. E., Alter, M. J., Bell, B. P., Finelli, L., Rodewald, L. E., Douglas, J. M., Janssen, R. S., & Ward, J. W. (2006) · PubMed · Cited by 1,132
Self-citationHIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
Thio, C. L., Seaberg, E. C., Skolasky, R., Phair, J., Visscher, B., Muñoz, A., & Thomas, D. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11913-1 · Cited by 1,099
Epidemiology of viral hepatitis and HIV co-infection
Alter, M. J. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.11.004 · Cited by 1,012 · cited 3×
“%) of persons who inject drugs (PWID) in a variety of settings (75) and 22.6% of PWID have evidence of past infection (75).”
BackgroundInfluential
Research works printed but not linked: 1
- Long SS, Prober CG, Fischer M. Principles and practice of pediatric infectious diseases. 5th ed. Amsterdam, the Netherlands: Elsevier; 2017.
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
“The last vaccine dose should not be given before 24 weeks of age.((89)) Only monovalent HBV vaccine should be used for preterm or term infants younger than 6 weeks.”
BackgroundSexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Hsu, Y.-C., Huang, D. Q., & Nguyen, M. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00760-9 · Cited by 632
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
Cornberg, M., Sandmann, L., Jaroszewicz, J., Kennedy, P., Lampertico, P., Lemoine, M., Lens, S., Testoni, B., Lai-Hung Wong, G., & Russo, F. P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.03.018 · Cited by 437
Surveillance of Vaccination Coverage Among Adult Populations —United States, 2018
Lu, P.-J., Hung, M.-C., Srivastav, A., Grohskopf, L. A., Kobayashi, M., Harris, A. M., Dooling, K. L., Markowitz, L. E., Rodriguez-Lainz, A., & Williams, W. W. (2021) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss7003a1 · Cited by 346
“In addition, vaccine can be administered to unvaccinated adults with diabetes aged ≥60 years at the discretion of their HCP (73,74).”
BackgroundSelf-citation
Metadata
- Authors
- Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P.
- Affiliations
- National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention (US)
- University of California, Berkeley (US)
- National Center for Emerging and Zoonotic Infectious Diseases (US)
- Corresponding author
- Schillie, Sarah
- Venue
- MMWR. Recommendations and Reports
- Published
- 2018-01-12
- Volume
- 67
- Issue
- 1
- Pages
- 1-31
- ISSN
- 1057-5987 (ISSN-L)
- 1545-8601
- PMC
- PMC5837403
- OpenAlex
- W2783773804
- Cited by
- 815
- References
- 160
- Citations by year
- 2026: 67 · 2025: 92 · 2024: 76 · 2023: 112 · 2022: 106 · 2021: 123 · 2020: 117 · 2019: 72 · 2018: 47
- FWCI
- 69.79
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- MMWR Recommendations and Reports (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- hepatitis B virus, hepatitis B vaccination, hepatitis B immunoglobulin, HBV DNA testing, post-exposure prophylaxis, occupational exposure, chronic hepatitis B, hepatitis B prevention
- MeSH terms
- Adolescent, Adult, Centers for Disease Control and Prevention, U.S., Child, Child, Preschool, Female, Hepatitis B, Humans, Immunization, Immunization Schedule, Immunization, Secondary, Infant, Infant, Newborn, Male, Pregnancy, United States, Hepatitis B Vaccines, Advisory Committees, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. https://app.cochat.ai/papers/10.15585/mmwr.rr6701a1
- The paper
- Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P. (2018). Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR. Recommendations and Reports. https://doi.org/10.15585/mmwr.rr6701a1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.